Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas

• Published in: Modern pathology 2008-04, Vol.21 (4), p.407-413
• Main Authors: Petri, Bart-Jeroen, Speel, Ernst-Jan M, Korpershoek, Esther, Claessen, Sandra M H, van Nederveen, Francien H, Giesen, Vivian, Dannenberg, Hilde, van der Harst, Erwin, Dinjens, Winand N M, de Krijger, Ronald R
• Format: Article
• Language: English
• Subjects: Adrenal Gland Neoplasms - genetics; Adrenal Gland Neoplasms - pathology; Adult; Aged; Biomarkers, Tumor - genetics; Cell cycle; Cell division; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 17 - genetics; Female; Genes; Genes, p53; Genomes; Humans; Hybridization; Immunohistochemistry; In Situ Hybridization, Fluorescence; Laboratory Medicine; Male; malignant; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Mutation; original-article; p53; Pathology; pheochromocytoma; Pheochromocytoma - genetics; Pheochromocytoma - pathology; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proteins; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Tumorigenesis; Tumors; Up-Regulation
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.3801013

Genetic changes in the tumorigenesis of sporadic pheochromocytomas are poorly understood, and there are no good markers to discriminate benign from malignant pheochromocytomas. p53 is a tumor suppressor gene and aberrations in this gene are frequently found in many tumor types. The role of p53 in pheochromocytoma tumorigenesis is unclear, with some studies suggesting that p53 mutations can be used to discriminate benign from malignant pheochromocytomas while other studies do not find such an association. Because most of these investigations were hampered by small series of tumors and the use of varying methods, we have performed a comprehensive analysis of p53 aberrations in a large series of pheochromocytomas. Comparative genomic hybridization analysis of 31 benign and 20 malignant tumors showed loss of the p53 locus at chromosome 17p13.1 in 2 3/51 (45%) cases, and most of these results were confirmed by fluorescence in situ hybridization. Forty-three tumors, including the malignant tumors and the tumors with loss of the p53 locus, were analyzed for p53 mutations in exons 5–8, but none were found. Furthermore, p53 immunohistochemistry on 35 cases revealed strong nuclear p53 expression in only two pheochromocytoma metastases, all other tumors being negative. We conclude that, although there is frequent loss of the p53 locus on 17p, the p53 gene does not appear to play a major role in pheochromocytoma tumorigenesis.